# Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

> **NCT01401244** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 30 (actual)

## Conditions studied

- Genetic Disorder
- Prader-Willi Syndrome
- Growth Disorder
- Idiopathic Short Stature
- Healthy

## Interventions

- **DRUG:** somatropin
- **DRUG:** somatropin

## Key facts

- **NCT ID:** NCT01401244
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-14
- **Primary completion:** 2011-09-27
- **Final completion:** 2011-09-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01401244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01401244, "Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01401244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*